#ASH18: Can Amgen break through the BCMA CAR-T line and take a BiTE of the multiple myeloma market? It won't be quick or easy
Amgen’s R&D group has been focusing considerable attention on its development of AMG 420 — a bispecific T-cell engager, or BiTE, in brand name parlance — that it believes can point them to a competitive position with the BCMA CAR-Ts now angling for first-mover advantage, and likely better than an antibody-drug conjugate. They came to San Diego with a first look at the Phase I data that include a high rate of response for one dose that could capture some support.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 83,000+ biopharma pros reading Endpoints daily — and it's free.